{{Rsnum
|rsid=799906
|Gene=NBR2
|Chromosome=17
|position=43126099
|Orientation=plus
|GMAF=0.4481
|Gene_s=BRCA1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 10.7 | 46.4 | 42.9
| HCB | 12.5 | 41.2 | 46.3
| JPT | 8.0 | 38.9 | 53.1
| YRI | 61.4 | 31.7 | 6.9
| ASW | 37.5 | 50.0 | 12.5
| CHB | 12.5 | 41.2 | 46.3
| CHD | 16.5 | 54.1 | 29.4
| GIH | 23.8 | 51.5 | 24.8
| LWK | 49.1 | 42.7 | 8.2
| MEX | 17.5 | 47.4 | 35.1
| MKK | 0.0 | 0.0 | 0.0
| TSI | 12.7 | 50.0 | 37.3
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs799906
|Name_s=BRCA1: -2804T>C
|Gene_s=NBR2, BRCA1
|Feature=
|Evidence=PubMed ID:18782836
|Annotation=This variant is in the promoter region of BRCA1 and has been shown to alter promoter acitivity in luciferase assay.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162370346
}}

{{PMID|12466288|OA=1
}} Haplotype and linkage disequilibrium architecture for human cancer-associated genes.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs799906
|overall_frequency_n=64
|overall_frequency_d=126
|overall_frequency=0.507936
|n_genomes=35
|n_genomes_annotated=0
|n_haplomes=52
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}